Thin Film Drug Market Scope
Thin-film drugs have proven to be an alternative to tablets or capsules because of their effective therapeutic results. The drugs are made of polymers that quickly dissolve when placed in the mouth or in the oral cavity and deliver the drug directly to the systemic circulation in the body. The thin film drugs have emerged as an alternative to tablets or capsules because of their efficient therapeutic results. The drugs are made up of polymers that quickly dissolve when placed in the mouth or in the oral cavity and deliver the drug directly to the systemic circulation in the body. The thin films are believed to be convenient to swallow, self-administer, and quickly dissolve, making them a versatile platform for drug delivery. There are various oral, buccal, sublingual, ocular, and transdermal routes of administration. In addition, the growing investment by pharmaceutical companies in research and development programs is fueling market growth.
The market study is being classified by Type (Transdermal Film and Oral Thin Film), by Application (Hospitals, Clinics and Others) and major geographies with country level break-up.
The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Thin Film Drug market throughout the predicted period.
GSK (United Kingdom), LTS (United States), J&J (United States), Indivior PLC (United States), Pfizer (United States), Sanofi (France), Church & Dwight (United States), tesa Labtec GmbH (Germany), Tapemark (United States), Prestige Consumer Healthcare (United States), Sun Pharmaceutical Industries Ltd. (India), MonoSol (United States), BioDelivery Sciences International, Inc. (United States), Arx (United States), ZIM (Israel) and NAL Pharma (Hong Kong) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are AdhexPharma (France), Aavishkar (India), IntelGenx Technologies Corporation (Canada) and APR (United States).
AdvanceMarketAnalytics has segmented the market of Global Thin Film Drug market by Type, Application and Region.
On the basis of geography, the market of Thin Film Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
Oral dissolving film is a thin film with an area of 1-20 cm2 (depends on the dose and drug loading) containing the drug. Drugs can be loaded up to a single dose of 30 mg. Formulation considerations (plasticizers, etc.) have been reported as important factors affecting the mechanical properties of the films. In the US Food and Drug Administration (US FDA), if the product is bioequivalent to that of the existing oral product the drug, an Abbreviated New Drug Application (ANDA) route is followed. There are no clinical studies associated with these generic approval processes (section 505 (j) of the Food, Drug, and Cosmetic Act). However, developed oral film product may exhibit a different pharmacokinetic profile compared to the existing marketed product. The ODF is categorized as ‘new dosage form’ and section 505 (b) (2) approval process needs to be followed.
- Increasing Demand for Effective Drug Delivery Systems
- The Rising Demand for Efficient Drug Delivery Routes and Its Adequacy
- The Increasing Demand for an Effective Way of Drug Delivery
- The Thin Film Drugs Have Surfaced As an Alternate to Tablets or Capsules Due To Its Efficient Therapeutic Results
- The Lower Manufacturing Costs of Thin Film Drugs
- Beneficial Government Initiatives
- The Growing Investments in Research and Development Programs by the Pharmaceutical Companies
- The Drawbacks Associated With the Conventional Forms of Dosage
- The Various Substitute Drugs Available
Key Target AudienceProviders of Thin Film Drug, End-Users, Potential Investors, Regulatory Bodies, Market Research Firms and Others
Customization available in this Study:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase